A new 68Ga-labeled dimeric FAP ligand to advance targeted PET imaging of cancer
hmFAP<sub>2</sub> markedly enhances FAP-targeting efficiency, providing higher binding affinity, improved tumor uptake, and reduced nonspecific distribution compared with its monomeric counterpart. The favorable imaging properties of hmFAP<sub>2</sub> position it as a promising candidate for translation into clinical PET imaging and as a potential scaffold for developing FAP-targeted theranostic agents.
Authors
- Bingqing Zou (ORCID: https://orcid.org/0009-0008-3906-8877)
- Diego R. Martín (ORCID: https://orcid.org/0000-0001-8810-0695)
- Zhen Yang (ORCID: https://orcid.org/0000-0001-9763-6766)
- James Nguyen (ORCID: https://orcid.org/0000-0003-0342-5621)
- Rhonda Holgate (ORCID: https://orcid.org/0000-0002-8725-3662)
- S. Zhang
- Jiankang Jin (ORCID: https://orcid.org/0000-0001-9864-9817)
- Jiexiao Chen
- Feng Li (ORCID: https://orcid.org/0000-0001-5892-6496)
- Yanping Yang (ORCID: https://orcid.org/0000-0003-2829-7486)
- Lan Zhou (ORCID: https://orcid.org/0000-0003-1291-534X)
- Chaitanya Kondam
- Muthuraju Sangu
- Philip Martin
- Junhua Mai
- Zhonglin Liu
Institutions
- Houston Methodist (US)
- Methodist Hospital (US)
- Methodist Hospital (US)
Publication Details
- Journal
- EJNMMI Radiopharmacy and Chemistry
- Published
- 2026-02-06
- DOI
- https://doi.org/10.1186/s41181-026-00424-4
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00